Cautious Roche Stresses: 'It's Not Only About APHINITY'
Executive Summary
Roche is suddenly sounding less optimistic about its Phase III APHINITY trial of Perjeta in the neoadjuvant breast cancer setting – stressing that 2017 will also bring three other key readouts for the company.
You may also be interested in...
Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business
Roche released positive headlines from its APHINITY trial examining use of Herceptin and Perjeta together in the adjuvant treatment of breast cancer, offering promise that its aging oncology franchise can be protected.
Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.